HCM 5010 Module 3 Manufacturers Written Assignment Example

$985 Million or $2.6 Billion a Drug, and a Medicare Price List for 2026: How Manufacturers Price and What Is Starting to Constrain Them

Student Name

Master of Science in Healthcare Management, Thomas Edison State University

HCM-5010: Organization of the Healthcare Value Chain

Mentor Name

Month Day, Year

$985 Million or $2.6 Billion a Drug, and a Medicare Price List for 2026: How Manufacturers Price and What Is Starting to Constrain Them

Manufacturers sit at the top of the health care value chain. Burns (2002) groups them into pharmaceutical companies, biotechnology firms, medical device makers and suppliers of medical-surgical products, and notes that their products account for a growing share of health spending and much of medicine's progress. This assignment analyzes how manufacturers set prices and justify them, how the device sector differs from the drug sector, and how a major policy change, Medicare's negotiation of drug prices, is altering the balance of power along the chain.

Research Costs and the Pricing Argument

Drug companies justify high prices by pointing to the cost and risk of research. Estimates vary widely. DiMasi et al. (2016), using confidential data from large companies, estimated the capitalized cost of developing a new approved drug at about $2.6 billion, including the cost of failures and the time value of money. Wouters et al. (2020), using public filings for 63 drugs approved between 2009 and 2018, estimated a median capitalized cost of $985.3 million and a mean of $1.34 billion, with large differences by therapeutic area.

The gap between these estimates matters because research cost is the industry's main argument against price limits. Both studies agree that developing drugs is expensive and risky, since most candidates fail. But research cost alone does not determine price. A patent gives a company a period without direct competition, and prices are set at what payers will bear, often far above the cost of manufacturing a single dose. Burns (2002) notes that manufacturers' pricing power is greatest when a product has no close substitute, which describes many new specialty drugs.

Devices Differ From Drugs

Medical device makers face a different market. Many devices reach the market through the Food and Drug Administration's 510(k) pathway by showing substantial equivalence to an existing device, which is faster and cheaper than the clinical trials required for new drugs; high-risk devices need premarket approval with clinical evidence. Devices are improved incrementally and often, so product lives are short, and competition comes from rival versions rather than from generics.

Device makers sell mainly to hospitals and surgeons rather than to patients, and their pricing reflects the bargaining described in Module 2. For commodity supplies, hospitals and purchasing groups hold the stronger hand. For physician preference items such as orthopedic implants and cardiac devices, manufacturers' relationships with surgeons give them more power, and prices vary considerably among hospitals for the same product.

Medicare Negotiation: A Shift in Power

The Inflation Reduction Act of 2022 allowed Medicare, for the first time, to negotiate the prices of certain high-spending drugs that have gone many years since approval with no generic or biosimilar rival. Ten drugs made up the first round, among them medicines for diabetes, heart failure and blood clots, and their negotiated prices took effect on January 1, 2026. Had the negotiated prices applied in 2023, Medicare would have spent about $6 billion less, a reduction of about 22 percent in net spending on those drugs (Centers for Medicare & Medicaid Services, 2024).

For manufacturers, negotiation changes the economics of older blockbuster products and may affect research decisions. Manufacturers warn that cutting revenue late in a product's life will discourage research, and they point out that pill-form chemical drugs face negotiation several years earlier than biologics, which may tilt research toward the latter. Supporters respond that the affected drugs had long periods of high prices and that the law targets products whose research costs have been recovered many times over. The evidence on long-term effects on innovation is not yet available, and a careful analysis should say so.

Effects Along the Chain

Negotiation's effects travel through the value chain. Medicare Part D plans and their PBMs will pay less for the negotiated drugs, which may reduce the rebates PBMs previously earned on them and change how formularies are built. Pharmacies dispense the drugs at the negotiated price but depend on reimbursement terms that the law does not control. Patients in Part D benefit directly when their cost sharing is based on lower prices, and the law's separate cap on out-of-pocket drug spending adds further protection. Manufacturers, in turn, may set higher launch prices for new drugs to offset expected negotiation later, which would shift costs to private payers.

This example illustrates the course's central idea: a change at one link alters bargaining and incentives at every other. For a hospital or health plan manager, the practical task is to anticipate those shifts, for instance by reviewing formulary contracts and pharmacy reimbursement terms before negotiated prices change the economics of a drug class.

Conclusion

Manufacturers' prices reflect patents, the absence of substitutes and payers' willingness to pay as much as research costs, whose estimates range from about $1 billion to $2.6 billion per new drug. Device makers face different regulation and customers, with pricing power concentrated in physician preference items. Medicare's negotiated prices, effective in 2026, mark the first direct federal limit on drug prices and will ripple through PBMs, pharmacies, patients and future launch prices, a reminder that manufacturers' power depends on the rest of the chain.

References

Burns, L. R., & Wharton School Colleagues. (2002). The health care value chain: Producers, purchasers, and providers. Jossey-Bass.

Centers for Medicare & Medicaid Services. (2024). Medicare drug price negotiation program: Negotiated prices for initial price applicability year 2026 [Fact sheet]. https://www.cms.gov/files/document/fact-sheet-negotiated-prices-initial-price-applicability-year-2026.pdf

DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20-33. https://doi.org/10.1016/j.jhealeco.2016.01.012

Wouters, O. J., McKee, M., & Luyten, J. (2020). Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA, 323(9), 844-853. https://doi.org/10.1001/jama.2020.1166